Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Reply to: “Do IL-17 inhibitors increase risk of respiratory tract infections?”

Journal of the American Academy of Dermatology(2020)10.1016/j.jaad.2020.06.1001Source: DataRank Database

Reply to: “Do IL-17 inhibitors increase risk of respiratory tract infections?” is a research paper published in Journal of the American Academy of Dermatology (2020). On theSindex it has a DataRank of 0.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access0 citations

Download PDF

Cite:

Linked data & code

doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (13 grants)OA: bronzeTopics (30)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (4)

Daniel B. Shin ORCID,Kevin Winthrop ORCID,Joel M. Gelfand ORCID,Marilyn T. Wan ORCID

Live enrichment

PubMed:32622146 PMC:PMC7329655 OpenAlex:https://openalex.org/W3038476863

National Institutes of Health

Grant: P30AR069589-03

NIAMS NIH HHS

Grant: P30 AR069589

National Institutes of Health

Grant: 5P30AR069589-03

Penn Resource-based Center to Support and Translate Skin DiseasesResearch

Celgene

Eli Lilly and Company

Pfizer

Bristol-Myers Squibb

Pfizer Inc

Janssen

Ortho Dermatologics

Novartis Corp

Sanofi

Abbvie

bronzeLicense: Elsevier TDM

journalhttp://www.jaad.org/article/S0190962220321010/pdf

publisherhttp://www.jaad.org/article/S0190962220321010/pdf

publisherhttps://api.elsevier.com/content/article/PII:S0190962220321010?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S0190962220321010?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.jaad.2020.06.1001

Fields of Study

Psoriasis: Treatment and PathogenesisPediatric health and respiratory diseasesAsthma and respiratory diseases03 medical and health sciences0302 clinical medicine

MeSH Terms

COVID-19SARS-CoV-2Biological ProductsDecision MakingHumansPsoriasisRespiratory Tract InfectionsInterleukin-17Pandemics

Keywords

MedicineRespiratory tract infectionsRespiratory tractIntensive care medicineRespiratory systemInternal medicineBiological ProductsSARS-CoV-2Decision MakingInterleukin-17COVID-19HumansPsoriasisDermatologyPandemicsJAAD Online

Sustainable Development Goals

SDG 0: Good health and well-being

Reply to: “Do IL-17 inhibitors increase risk of respiratory tract infections?”

FAIR Checklist

Authors (4)

Funding (13 grants)

Open Access

Topics

Annotations (Europe PMC)